On the last follow-up, the patient lost significant weight with better control of diabetes (ranging from 5.0 to 5.7 mmol/L in a fasting state and post-meal capillary glucose <8.2 mmol/L using a glucometer at home) without any evidence of hypoglycemia after the initiation of semaglutide, and the dose of insulin was reduced significantly. This evidence concerns the gene INS and Hypoglycemia.